5.1.2.e Woo

From:
Sent:
To:
Subject:

5.1.2.e Woo woensdag 27 maart 2019 14:25 5.1.2.e Woo FW: Public accessibility of Bayer-owned glyphosate safety studies

Zie onderstaande ter info.

Van: 5.1.2.e Woo Verzonden: woensdag 27 maart 2019 14:24 Aan: Leeuw, ir. J. de (Johan); Duijn, dr. ir. L.P. van (Luuk); 5.1.2.e Woo

Onderwerp: FW: Public accessibility of Bayer-owned glyphosate safety studies

Beste collega's,

Zie onderstaand bericht.

Met groet, 5.1.2.e Woo

Van: 5.1.2.e Woo @bayer.com] Verzonden: woensdag 27 maart 2019 13:13 Aan: 5.1.2.e Woo

CC: 5.1.2.e Woo

Onderwerp: Public accessibility of Bayer-owned glyphosate safety studies

Dear 5.1.2.e Woo,

As you are well aware, the safety of glyphosate and other crop protection tools continues to be a topic that drives public conversation. Bayer understands people want more information regarding the safety of our products. As an industry leader, we continue to embrace our responsibility to do a better job communicating about the safety of our products by opening-up and giving interested citizens access to the safety studies we have submitted to regulatory authorities under the substance approval process. Improving access to the science behind our products is a key part of what we refer to as our Transparency Initiative. (cropscience-transparency.bayer.com.)

We are reaching out to you today because we are marking another development in our initiative: we are making the Bayer-owned glyphosate studies available on our website. This step follows last December's publication of more than 300 glyphosate safety study summaries. Access will now be enabled to all 107 Bayer-owned glyphosate safety study reports that were submitted to the European Food Safety Authority (EFSA) as part of the substance authorization process in the European Union (EU).

As with the other substances included within our Transparency Initiative so far, we are focusing on safety studies submitted under the substance authorization process for plant protection products in the EU to the EFSA. This includes studies on toxicology, residues, E-fate, and ecotoxicology on the active substance, as well as a representative formulation. We are only including studies that have been submitted for uses in the EU market, but not those that have been submitted in the U.S. and other countries for specific product formulations. The studies submitted to EFSA may also cover some studies that have been submitted to other regulatory authorities across the globe.

We can provide access only to those safety studies that are fully owned by Bayer. Bayer cannot offer access to studies that are owned by other companies. In the EU, glyphosate safety studies for the most recent active substance renewal were submitted with a joint submission under the so-called "Glyphosate Task Force" (GTF): a consortium of companies joining resources and efforts to renew the European glyphosate registration. Safety studies on glyphosate conducted by the GTF, and the data contained within these studies, are not wholly owned by Bayer. As a result, we are not automatically at liberty to disclose this information. The full study reports are available on demand for non-commercial use upon request on our transparency website via an online order form. Recipients are granted a license to use one copy of the respective document. Any distribution, reproduction or publication requires the consent of Bayer AG (or its respective affiliate). Any use of the document or its content for regulatory or any other commercial purpose is prohibited and constitutes a violation of the underlying license agreement. For further details, please click <u>here</u>. If you have any questions or would like to learn more, please do not hesitate to reach out. Further information around the initiative can also be found in the FAQ section of our website.

Best regards,

Best regards,

5.1.2.e Woo

Bayer - Crop Science

Bayer Agriculture BVBA Tervurenlaan 270-272 1150, Brussels Belgium Tel: 5.1.2.e Woo Fax: 5.1.2.e Woo Mobile: 5.1.2.e Woo E-mail: 5.1.2.e Woo Web: http://www.bayer.com

/// Follow Bayer on:

/// Twitter /// Facebook /// Instagram /// LinkedIn /// YouTube